Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Shantha Biotechnics Consents to Manufacture Dengue Vaccine

  • Shantha Biotechnics will manufacture InViragen’s dengue vaccine candidate under an agreement between the two companies. This vaccine will be used to complete preclinical studies and initiate testing of its safety and efficacy in humans.

    The vaccine was designed by collaborators at the CDC to protect against all four of the dengue viruses. "InViragen and the CDC are using innovative recombinant technologies to create a novel vaccine," says Varaprasad Reddy, M.D., managing director of Shantha Biotechnics.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »